Ginkgo BioworksDNA
DNA
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
290% more call options, than puts
Call options by funds: $29.6M | Put options by funds: $7.59M
50% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]
49% more capital invested
Capital invested by funds: $215M [Q3] → $319M (+$104M) [Q4]
38% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 26
10.79% more ownership
Funds ownership: 61.13% [Q3] → 71.92% (+10.79%) [Q4]
5% more funds holding
Funds holding: 158 [Q3] → 166 (+8) [Q4]
8% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 39
Research analyst outlook
We haven’t received any recent analyst ratings for DNA.
Financial journalist opinion
Based on 6 articles about DNA published over the past 30 days
Neutral
Business Wire
13 hours ago
Plex Research Partners With Ginkgo Bioworks on Artificial Intelligence (AI)-Powered Drug Discovery to Identify Novel Disease Mechanisms and Pathways
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Plex Research is partnering with Ginkgo Bioworks to use AI to deepen understanding of the mechanisms of action of existing drugs.
Neutral
Zacks Investment Research
2 days ago
Here's Why Ginkgo Bioworks (DNA) is Poised for a Turnaround After Losing -28.84% in 4 Weeks
The heavy selling pressure might have exhausted for Ginkgo Bioworks (DNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Neutral
Zacks Investment Research
1 week ago
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $6.59, denoting a -0.9% change from the preceding trading day.
Positive
Zacks Investment Research
1 week ago
Ginkgo Bioworks Holdings, Inc. (DNA) Surpasses Market Returns: Some Facts Worth Knowing
Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $7.27, moving +1.39% from the previous trading session.
Negative
Zacks Investment Research
2 weeks ago
After Plunging -52.33% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA)
The heavy selling pressure might have exhausted for Ginkgo Bioworks (DNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Positive
Zacks Investment Research
4 weeks ago
Ginkgo Bioworks (DNA) Upgraded to Buy: Here's Why
Ginkgo Bioworks (DNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Negative
Seeking Alpha
1 month ago
Ginkgo Bioworks: Revenue Struggles Continue
Ginkgo Bioworks missed Q4 revenue estimates and issued extremely weak 2025 revenue guidance. Despite improving losses and cash burn, financial flexibility is decreasing, with cash reserves dropping significantly over the past year. The company's valuation is low, but declining revenues and high stock-based compensation pose risks.
Negative
Seeking Alpha
1 month ago
2025 Is Make Or Break For Ginkgo Bioworks
Ginkgo Bioworks' restructuring has resulted in a dramatic reduction in cash burn in recent quarters. Ginkgo remains a long way from breakeven though and growth is expected to be poor in 2025. Unless Ginkgo can demonstrate continuous progress in 2025, its stock is likely to remain under pressure due to its shrinking cash runway.
Negative
Benzinga
1 month ago
Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Wednesday.
Neutral
Seeking Alpha
1 month ago
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2024 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q4 2024 Earnings Conference Call February 25, 2025 5:30 PM ET Company Participants Joseph Fridman - Director, Communications and Corporate Affairs Jason Kelly - Founder, CEO & Director Mark Dmytruk - CFO Jason Kelly - Founder, CEO & Director Conference Call Participants Jason Lai - Morgan Stanley Evie Kslosky - Goldman Mark Massaro - BTIG Brendan Smith - TD Cowen Matt Larew - William Blair & Company Joseph Fridman Good evening. I'm Joseph Fridman, Director of Communications and Corporate Affairs here at Ginkgo, where it's my fifth year.
Charts implemented using Lightweight Charts™